Ophthalmic gene therapy company restoring and improving the vision of patients with retinal diseases
Location: United States, Florida, Alachua
Employees: 51-200
Phone: +44 20 3398 7880
Total raised: $170M
Founded date: 2023
Investors 1
| Date | Name | Website |
| 13.08.2024 | Syncona Pa... | synconaltd... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.07.2024 | Series B | $170M | - |
Mentions in press and media 8
| Date | Title | Description |
| 24.07.2024 | Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer | CEO Dave Fellows named non-Executive Chairman of the Board Executive appointments follow $170 million Series B fundraise LONDON and CAMBRIDGE, Mass., July 24, 2024 /PRNewswire/ -- Beacon Therapeutics Holdings Limited ('Beacon' or 'the Compa... |
| 12.07.2024 | Beacon Therapeutics Secures $170 Million in Series B Funding for Advancement of Ophthalmic Gene Therapies | Beacon Therapeutics, a pioneering ophthalmic gene therapy company, has achieved a significant milestone by raising a substantial $170 million in Series B funding. This funding round, spearheaded by Forbion and bolstered by the support of Sy... |
| 12.07.2024 | Beacon Therapeutics: Ophthalmic Gene Therapy Company Raises $170 Million | Beacon Therapeutics, a leading ophthalmic gene therapy company with a goal of saving and restoring the vision of patients with blinding retinal diseases, announced it has raised $170 million in Series B funding. Forbion led the financing – ... |
| 09.07.2024 | Beacon Therapeutics Raises $170M in Series B Funding | Beacon Therapeutics, a London, UK-based ophthalmic gene therapy company, raised $170M in Series B funding. The round, which brought the total amount to $290M, was led by Forbion, with participation from Syncona Limited, Oxford Science Enter... |
| 03.07.2024 | Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial | Beacon Therapeutics has raised a $170 million series B, which the U.K.-based gene therapy biotech will use to push its eye disease candidates through clinical trials. London-based Beacon (which also has a base in Massachusetts) launched wit... |
| 03.07.2024 | Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies | Financing led by life sciences venture capital firm Forbion, alongside existing investors Syncona and Oxford Science Enterprises, as well as new investors TCGX and Advent Life Sciences Round will accelerate the development of lead asset AGT... |
| 12.06.2023 | Beacon Therapeutics Raises $120M in Funding | Beacon Therapeutics, an Oxford, UK-based ophthalmic gene therapy company, raised $120M in funding. The round saw participation from Syncona Limited, with additional investors including Oxford Science Enterprises. The company intends to use ... |
| - | Beacon Therapeutics | “Home - Beacon Therapeutics ” |